Compare WKHS & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | LEXX |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 17.4M |
| IPO Year | N/A | N/A |
| Metric | WKHS | LEXX |
|---|---|---|
| Price | $5.38 | $0.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $21.00 | $1.50 |
| AVG Volume (30 Days) | 225.4K | ★ 1.5M |
| Earning Date | 11-10-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $705,923.00 |
| Revenue This Year | $92.70 | $13.35 |
| Revenue Next Year | $34.00 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 16.73 | ★ 52.05 |
| 52 Week Low | $5.01 | $0.46 |
| 52 Week High | $118.50 | $2.30 |
| Indicator | WKHS | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 43.75 |
| Support Level | $5.20 | $0.46 |
| Resistance Level | $6.00 | $0.72 |
| Average True Range (ATR) | 0.40 | 0.09 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 35.35 | 93.07 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.